What is Vertex Pharmaceuticals Incorporated's current stock price?

Vertex Pharmaceuticals Incorporated (VRTX) currently trades at USD 434.31. Track real-time price changes and historical performance on AllInvestView.

What sector is Vertex Pharmaceuticals Incorporated in?

Vertex Pharmaceuticals Incorporated operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Vertex Pharmaceuticals Incorporated

🧾 Earnings Recap – Q1 2026

Vertex's Q1 results were largely in line with expectations, reflected in a flat market reaction of +0.1%. Despite solid revenue growth and progress across multiple franchises, the stock's muted response suggests investors found limited reasons for enthusiasm beyond steady execution.

Total product revenue reached $2.99 billion, marking 8% year-over-year growth.
Products in new disease areas, including KASJEVY and GERNAVICS, contributed about 25% of total product revenue growth.
Commercial milestones include AlifTrack surpassing $1 billion in cumulative revenue and over 500 patients starting KASJEVY treatment.
R&D progress featured rapid regulatory submissions for POBI in IgAN and KASJEVY in pediatric sickle cell disease/beta thalassemia, with clinical trials advancing across various indications.
VX-522 mRNA therapy program was discontinued due to tolerability issues, eliminating potential upside from this next-generation CF treatment.

View full recap page

Vertex Pharmaceuticals Incorporated Analysis (VRTX)

United States Health Care Official Website Stock

Is Vertex Pharmaceuticals Incorporated a good investment? Vertex Pharmaceuticals Incorporated (VRTX) is currently trading at 434.31 USD. Market analysts have a consensus price target of 549.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 25.90. This valuation is generally in line with the broader market.

Earnings Schedule: Vertex Pharmaceuticals Incorporated is expected to release its next earnings report on Aug. 3, 2026. The market consensus estimate for Forward EPS is 21.56.

Investor FAQ

Does Vertex Pharmaceuticals Incorporated pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 3, 2026. The company currently has a trailing EPS of 16.87.

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Split Date	Split Ratio to 1
Aug. 24, 2000	2.000000

Split Date

Split Ratio to 1

Aug. 24, 2000

2.000000

Vertex Pharmaceuticals Incorporated VRTX Open Vertex Pharmaceuticals Incorporated in new tab

Vertex Pharmaceuticals Incorporated

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features